Cannabis and its derivatives: Review of medical use

Journal of the American Board of Family Medicine

Volumn 24, Issue 4, 2011, Pages 452-462

  Leung, Lawrence ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Cannabis; Clinical effects; Controversy; Drug therapy; Marijuana; Substance abuse

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; ALUMINUM; CADMIUM; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; CANNABIS; CANNABIS DERIVATIVE; CP 47 497; DEXANABINOL; DRONABINOL; JWH 073; MORPHINE; NABILONE; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEART FAILURE; ADJUVANT THERAPY; ALZHEIMER DISEASE; ANALGESIC ACTIVITY; ANOREXIA; ANXIETY; ARTICLE; ASPERGILLUS; BLADDER DYSFUNCTION; BLOOD PRESSURE FLUCTUATION; CACHEXIA; CANNABIS ADDICTION; CAPSAICIN INDUCED PAIN; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PAIN; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG CONTAMINATION; DRUG CONTROL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG FATALITY; DRUG RECEPTOR BINDING; DRUG SEEKING BEHAVIOR; DRUG USE; EPILEPSY; EUPHORIA; FIBROMYALGIA; GILLES DE LA TOURETTE SYNDROME; GLAUCOMA; GLIOBLASTOMA; HEALTH CARE POLICY; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LAW; LAW ENFORCEMENT; LEGAL ASPECT; LUNG FUNCTION; LUNG INFECTION; MEMORY DISORDER; MULTIPLE SCLEROSIS; MUSCLE SPASM; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PAIN; PASSIVE SMOKING; POSTOPERATIVE PAIN; PSYCHOMOTOR RETARDATION; PSYCHOMOTOR SEQUELAE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SINGLE DRUG DOSE; SOCIAL ASPECT; SPASTICITY; SPINAL CORD DISEASE; SPINAL CORD NERVE CELL; TACHYCARDIA; TERMINAL CARE; UNITED STATES; WEIGHT REDUCTION;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; CANNABINOIDS; CANNABIS; DRUG SYNERGISM; HUMANS; MARIJUANA ABUSE; MARIJUANA SMOKING; NEURALGIA; PAIN; PHYTOTHERAPY; STREET DRUGS; UNITED STATES;

EID: 79960196882     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2011.04.100280     Document Type: Article

References (93)

1. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006;28(2):153-7. (Pubitemid 44086488)
2. Touw M. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs 1981;13(1):23-34. (Pubitemid 11028276)
3. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374(9698):1383-91.
4. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001;178:101-6.
5. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998;83(2):393-411. (Pubitemid 28062631)
6. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232(1):54-61.
7. Egan D, Miron JA. The budgetary implications of marihuana prohibition. In: Earleywine M, ed. Pot Politics: Marijuana and the Costs of Prohibition. New York: Oxford University Press; 2007:17-39.
8. Hoffmann DE, Weber E. Medical marijuana and the law. N Engl J Med 2010;362(16):1453-7.
9. MacDonald J. Medical marijuana: informational resources for family physicians. Am Fam Physician 2009;80(8):779.
10. Aggarwal SK, Kyashna-Tocha M, Carter GT. Dosing medical marijuana: rational guidelines on trial in Washington State. Med Gen Med 2007;9(3):52.
11. O'Connell TJ, Bou-Matar CB. Long term marijuana users seeking medical cannabis in California (2001-2007): demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants. Harm Reduct J 2007;4:16.
12. Single E, Christie P, Ali R. The impact of cannabis decriminalisation in Australia and the United States. J Public Health Policy 2000;21(2):157-86. (Pubitemid 30396142)
13. US Department of Veterans Affairs. Medical marijuana. VHA Directive 2010-035. Washington DC: Veterans Health Administration; July 2010. Available at: http://www.va.gov/vhapublications/ViewPublication.asp?pub-ID=2276. Accessed .
14. Lifland JB. States reassess medical marijuana laws after warnings. 3 May 2011. Available at: http://yourlife.usatoday.com/health/medical/story/2011/05/ States-reassess-medical-marijuana-laws-after-warnings/46756064/1#uslPageReturn. Accessed 31 May 2011.
15. Health Canada. Fact sheet-medical access to marihuana. 2008. Available at: http://www.hc-sc.gc.ca/dhpmps/marihuana/law-loi/fact-sheet-infofiche-eng. php. Accessed 31 May 2011.
16. Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998;352(9140):1611-6. (Pubitemid 28515256)
17. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007;4(8):1744-69.
18. Moir D, Rickert WS, Levasseur G, et al. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. Chem Res Toxicol 2008;21(2):494-502.
19. Reid PT, Macleod J, Robertson JR. Cannabis and the lung. J R Coll Physicians Edinb 2010;40(4):328-34.
20. Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 2005;63(2):93-100. (Pubitemid 41167514)
21. Lehavi A, Shay M, Gilony C, Even L. [Marijuana smoking and paroxysmal atrial fibrillation]. Harefuah 2005;144(1):2-3, 72.
22. Baranchuk A, Johri AM, Simpson CS, Methot M, Redfearn DP. Ventricular fibrillation triggered by marijuana use in a patient with ischemic cardiomyopathy: a case report. Cases J 2008;1(1):373.
23. Basnet S, Mander G, Nicolas R. Coronary vasospasm in an adolescent resulting from marijuana use. Pediatr Cardiol 2009;30(4):543-5.
24. Bailly C, Merceron O, Hammoudi N, Dorent R, Michel PL. Cannabis induced acute coronary syndrome in a young female. Int J Cardiol 2010;143(1):e4-6.
25. Dwivedi S, Kumar V, Aggarwal A. Cannabis smoking and acute coronary syndrome: two illustrative cases. Int J Cardiol 2008;128(2):e54-7.
26. Kocabay G, Yildiz M, Duran NE, Ozkan M. Acute inferior myocardial infarction due to cannabis smoking in a young man. J Cardiovasc Med (Hagerstown) 2009;10(9):669-70.
27. Cappelli F, Lazzeri C, Gensini GF, Valente S. Cannabis: a trigger for acute myocardial infarction? A case report. J Cardiovasc Med (Hagerstown) 2008;9(7):725-8.
28. Fergusson DM, Horwood LJ, Northstone K. Maternal use of cannabis and pregnancy outcome. BJOG 2002;109(1):21-7.
29. Zuckerman B, Frank DA, Hingson R, et al. Effects of maternal marijuana and cocaine use on fetal growth. N Engl J Med 1989;320(12):762-8. (Pubitemid 19093542)
30. English DR, Hulse GK, Milne E, Holman CD, Bower CI. Maternal cannabis use and birth weight: a meta-analysis. Addiction 1997;92(11):1553-60. (Pubitemid 27499566)
31. van Gelder MM, Reefhuis J, Caton AR, Werler MM, Druschel CM, Roeleveld N. Characteristics of pregnant illicit drug users and associations between cannabis use and perinatal outcome in a population-based study. Drug Alcohol Depend 2010;109(1-3):243-7.
32. Schempf AH, Strobino DM. Illicit drug use and adverse birth outcomes: is it drugs or context? J Urban Health 2008;85(6):858-73.
33. Le Bec PY, Fatseas M, Denis C, Lavie E, Auriacombe M. [Cannabis and psychosis: search of a causal link through a critical and systematic review]. Encephale 2009;35(4):377-85.
34. Shapiro GK, Buckley-Hunter L. What every adolescent needs to know: cannabis can cause psychosis. J Psychosom Res 2010;69(6):533-9.
35. Dragt S, Nieman DH, Becker HE, et al. Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry 2010;55(3):165-71.
36. Miller NS, Gold MS. The diagnosis of marijuana (cannabis) dependence. J Subst Abuse Treat 1989;6(3):183-92. (Pubitemid 19220640)
37. Swift W, Gates P, Dillon P. Survey of Australians using cannabis for medical purposes. Harm Reduct J 2005;2:18.
38. Latimer W, Zur J. Epidemiologic trends of adolescent use of alcohol, tobacco, and other drugs. Child Adolesc Psychiatr Clin N Am 2010;19(3):451-64.
39. McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W. Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies. Int J Drug Policy 2010;21(1):10-9.
40. Degenhardt L, Coffey C, Carlin JB, Swift W, Moore E, Patton GC. Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. Br J Psychiatry 2010;196:290-5.
41. Temple EC, Brown RF, Hine DW. The 'grass ceiling': limitations in the literature hinder our understanding of cannabis use and its consequences. Addiction 2011;106(2):238-44.
42. Drug Enforcement Adminstration, US Department of Justice. Herbal high-legal synthetic cannabinoids produce illicit marijuana effects: spice, k2 and other "legal" products sold as marijuana alternatives. June 2010. Available at: www.wyptac.org/upload/DEA%20K2%20Fact%20Sheet.pdf. Accessed 31 May 2011.
43. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 2010;160(3):585-93.
44. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004;62(11):2098-100. (Pubitemid 38738230)
45. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 2003;102(1-2):211-6. (Pubitemid 36298878)
46. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008;9(6):506-21.
47. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010;182(14):E694-701.
48. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007;68(7):515-21.
49. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009;34(3):672-80.
50. Bushlin I, Rozenfeld R, Devi LA. Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 2010;10(1):80-6.
51. Yesilyurt O, Dogrul A, Gul H, et al. Topical cannabinoid enhances topical morphine antinociception. Pain 2003;105(1-2):303-8. (Pubitemid 37162500)
52. Yesilyurt O, Dogrul A. Lack of cross-tolerance to the antinociceptive effects of systemic and topical cannabinoids in morphine-tolerant mice. Neurosci Lett 2004;71(2-3):122-7. (Pubitemid 39440757)
53. Elikkottil J, Gupta P, Gupta K. The analgesic potential of cannabinoids. J Opioid Manag 2009;5(6):341-57.
54. Cox ML, Haller VL, Welch SP. Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol 2007;567(1-2):125-30. (Pubitemid 46782831)
55. Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006;530(1-2):54-8. (Pubitemid 43037124)
56. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract 2004;17(1):59-67.
57. Sandyk R, Awerbuch G. Marijuana and Tourette's syndrome. J Clin Psychopharmacol 1998;8(6):444-5.
58. Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 1993;7(4):389-91. (Pubitemid 23362786)
59. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980;87(3):222-8. (Pubitemid 10130590)
60. Wallace M, Schulteis G, Atkinson JH, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007;107(5):785-96. (Pubitemid 351325971)
61. Kraft B, Frickey NA, Kaufmann RM, et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. Anesthesiology 2008;109(1):101-10.
62. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10(4):417-24. (Pubitemid 39117339)
63. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005;76(12):1664-9. (Pubitemid 41697631)
64. 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002;35(2):57-61.
65. Muller-Vahl KR, Schneider U, Prevedel H, et al. 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 2003;64(4):459-65. (Pubitemid 36547292)
66. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987;7(1):39-50.
67. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ. Lack of analgesic efficacy of oral-9-tetrahydrocannabinol in postoperative pain. Pain 2003;106(1-2):169-72. (Pubitemid 37329627)
68. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D. Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 2004;8(2):173-7.
69. Guzman M, Duarte MJ, Blazquez C, et al. A pilot clinical study of 9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006;95(2):197-203. (Pubitemid 44050919)
70. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997;12(9):913-9. (Pubitemid 27420571)
71. Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 2006;185(4):524-8.
72. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10(2):89-97.
73. Pooyania S, Ethans K, Szturm T, Casey A, Perry D. A randomized, double-blinded, crossover pilot study assessing the effect of nabilone on spasticity in persons with spinal cord injury. Arch Phys Med Rehabil 2010;91(5):703-7.
74. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008;9(2):164-73.
75. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 2007;133(1-3):210-20. (Pubitemid 350141682)
76. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17(1):21-9. (Pubitemid 36230977)
77. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65(6):812-9. (Pubitemid 41362120)
78. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Multiple Sclerosis 2004;10(4):425-33. (Pubitemid 39117340)
79. Bocker KB, Gerritsen J, Hunault CC, Kruidenier M, Mensinga TT, Kenemans JL. Cannabis with high Delta(9)-THC contents affects perception and visual selective attention acutely: an event-related potential study. Pharmacol Biochem Behav 2010;96(1):67-74.
80. McLaren J, Swift W, Dillon P, Allsop S. Cannabis potency and contamination: a review of the literature. Addiction 2008;103(7):1100-9. (Pubitemid 351832248)
81. Kagen SL, Kurup VP, Sohnle PG, Fink JN. Marijuana smoking and fungal sensitization. J Allergy Clin Immunol 1983;71(4):389-93. (Pubitemid 13124946)
82. Kurup VP, Resnick A, Kagen SL, Cohen SH, Fink JN. Allergenic fungi and actinomycetes in smoking materials and their health implications. Mycopathologia 1983;82(1):61-4. (Pubitemid 13078622)
83. Ungerleider JT, Andrysiak T, Tashkin DP, Gale RP. Contamination of marihuana cigarettes with pathogenic bacteria-possible source of infection in cancer patients. Cancer Treat Rep 1982;66(3):589-91. (Pubitemid 12084962)
84. Chusid MJ, Gelfand JA, Nutter C, Fauci AS. Pulmonary aspergillosis, inhalation of contaminated marijuana smoke, chronic granulomatous disease. Ann Intern Med 1975;82(5):682-3.
85. Exley C, Begum A, Woolley MP, Bloor RN. Aluminum in tobacco and cannabis and smoking-related disease. Am J Med 2006;119(3):276.e9-211.
86. Shi G, Cai Q. Cadmium tolerance and accumulation in eight potential energy crops. Biotechnol Adv 2009;27(5):555-61.
87. Delourme J, Delattre C, Godard P, Steenhouwer F, Just N. [Respiratory consequences of inhalation of adulterated cannabis]. Rev Mal Respir 2009;26(5):552-6.
88. Viana M, Querol X, Alastuey A, et al. Drugs of abuse in airborne particulates in urban environments. Environ Int 2010;36(6):527-34.
89. Rohrich J, Schimmel I, Zorntlein S, et al. Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop. J Anal Toxicol 2010;34(4):196-203.
90. Lister J. Cannabis controversy and other sundry troubles. N Engl J Med 1969;280(13):712-4.
91. Ren Y, Whittard J, Higuera-Matas A, Morris CV, Hurd YL. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 2009;29(47):14764-9.
92. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008;30(3):271-80.
93. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006;39(4):421-9.